Augmentation of the immune response to influenza vaccine by acetylsalicylic acid: a clinical trial in a geriatric population.
The purpose of this placebo-controlled, double-blind, randomized trial was to evaluate the efficacy of oral acetylsalicylic acid (ASA), a comparatively safe, inexpensive biological response modifier, as an adjuvant to influenza vaccination in a geriatric population. 281 healthy adults, 65 years or older, received influenza vaccine and were randomized to ASA or placebo. Serum antibody against influenza A/Beijing and B/Panama, influenza antigen-stimulated blastogenesis and antigen-stimulated interleukin-2 production by peripheral blood mononuclear cells in vitro were increased following vaccination. Blastogenic response and interleukin-2 production increased to a similar extent in the two treatment groups. The proportion of participants with a 4-fold rise in specific antibody directed against influenza A/Beijing was greater among ASA recipients (p < 0.05). This difference was more marked in subjects > 75 years old (p < 0.01).
Hsia
J
J
Division of Cardiology, George Washington University, Washington, DC, USA.
Tang
T
T
Parrott
M
M
Rogalla
K
K
D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000097:blood; D000914:Antibodies, Viral / Q000096:biosynthesis*; D000937:Antigen-Antibody Reactions / Q000187:drug effects; D001241:Aspirin / Q000008:administration & dosage / Q000494:pharmacology*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D009980:Influenza A virus / Q000276:immunology*; D009981:Influenza B virus / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000276:immunology*; D007251:Influenza, Human / Q000517:prevention & control; D007376:Interleukin-2 / Q000096:biosynthesis; D016014:Linear Models; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D007252:Influenza Vaccines; D007376:Interleukin-2; D001241:Aspirin